International Journal of Hematology

, Volume 107, Issue 1, pp 83–91 | Cite as

Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

  • Yukio Kobayashi
  • Wataru Munakata
  • Michinori Ogura
  • Toshiki Uchida
  • Masafumi Taniwaki
  • Tsutomu Kobayashi
  • Fumika Shimada
  • Masataka Yonemura
  • Fumiko Matsuoka
  • Takeshi Tajima
  • Kimikazu Yakushijin
  • Hironobu Minami
Original Article


The current therapy for high-risk myelodysplastic syndrome (MDS) involves repeated cycles of the DNA demethylating agent 5-azacitidine (5-Aza), but combination treatments have been proposed to improve patient outcomes. We performed a phase Ib study to investigate the safety and tolerability of 5-Aza (75 mg/m2) combined with the histone deacetylase inhibitor panobinostat (PAN) in adult Japanese patients with MDS or chronic myelomonocytic leukemia (CMML). Eleven patients were enrolled; five received 20 mg PAN + 5-Aza and six received 30 mg PAN + 5-Aza. All patients in the 20 mg PAN cohort had MDS, while two in the 30 mg PAN cohort had MDS and three had CMML. All patients experienced ≥1 adverse event (AE) related to the study treatment, and five discontinued the study treatment because of AEs. One patient in each group exhibited dose-limiting toxicities: lung infection (PAN 20 mg + 5-Aza) and cellulitis (PAN 30 mg + 5-Aza). PAN exposure increased with ascending doses, and combination therapy did not affect PAN plasma trough concentrations. In summary, 20 or 30 mg PAN combined with 5-Aza was safe and tolerable in adult Japanese patients with CMML or MDS.

Study registration Identifier: NCT01613976.


Azacitidine AML CMML Myelodysplastic syndromes Panobinostat 



This study was supported by an independent data monitoring committee comprising three physicians: Dr. Yasushi Miyazaki of Nagasaki University, Dr. Keiya Ozawa of Jichi Medical University (currently of the Institute of Medical Science, The University of Tokyo), and Dr. Tomoki Naoe of Nagoya Medical Center. A medical expert consultancy agreement was made with Dr. Masamitsu Yanada of Fujita Health University. The authors thank J. Ludovic Croxford, Ph.D., of Edanz Medical Writing, on behalf of Springer Healthcare Communications, for providing medical writing support. This assistance was funded by Novartis Pharmaceuticals Japan.

Conflict of interest

YK received research funding from Novartis during the conduct of the study. FS, MY, FM, and TT are employees of Novartis. HM reports grants from Novartis during the conduct of the study; as well as grants from Fuji Film RI Pharma, AstraZeneca, Yakult Honsha, Berhringer Ingelheim, Astellas, Merck Serono, Sanofi, MSD, Nihon Shinyaku, Teijin Pharma, and Dainippon Sumitomo; grants and personal fees from Taisho Toyama Pharmaceutical, Novartis, Eisai, Kyowa Hakko Kirin, Chugai, Bristol Myers Squibb, Taiho, Daiichi-Sankyo, Ono, Pfizer, Eli Lilly, Takeda Pharmaceutical, and Asahi Kasei Pharma, and personal fees from Bayer, Kowa, Nippon Chemiphar, and Mochida Pharmaceutical, outside the submitted work. MO reports grants from SymBio and Celltrion and personal fees from Meiji Seika Pharma, Mundipharma, Celltrion, AstraZeneca, Takeda, Jansen Pharma, and Celgene, outside the submitted work. The remaining authors declare that they have no conflicts of interest. This industry-led study was sponsored by Novartis, who also supplied the study drugs.


  1. 1.
    Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005;19:301–19.CrossRefPubMedGoogle Scholar
  2. 2.
    Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117:7121–5.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847–52.CrossRefPubMedGoogle Scholar
  4. 4.
    Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24:469–73.CrossRefPubMedGoogle Scholar
  5. 5.
    Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–903.CrossRefPubMedGoogle Scholar
  9. 9.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Moe-Behrens GH, Pandolfi PP. Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol. 2003;7:139–59.PubMedGoogle Scholar
  11. 11.
    Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 2003;3:187–99.CrossRefPubMedGoogle Scholar
  13. 13.
    Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008;45:23–30.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs. 2013;22:1211–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, et al. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012;87:127–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ottmann OG, DeAngelo DJ, Garcia-Manero G, Lübbert M, Jillella A, Sekeres MA et al. Determination of a phase II dose of panobinostat in combination with 5-azacitidine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. American Society of Hematology (ASH)—annual meeting 2011, Abs # 459. Accessed 19 Jan 2016.
  17. 17.
    Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, et al. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia. 2014;28:696–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther. 2010;9:2309–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res. 2014;20:724–35.CrossRefPubMedGoogle Scholar
  20. 20.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.PubMedGoogle Scholar
  21. 21.
    Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, et al. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs. 2012;30:1096–106.CrossRefPubMedGoogle Scholar
  22. 22.
    Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27:2420–39.CrossRefPubMedGoogle Scholar
  24. 24.
    Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.CrossRefPubMedGoogle Scholar
  25. 25.
    Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526.CrossRefPubMedGoogle Scholar
  27. 27.
    DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27:1628–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017;52:50–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol. 2016;172:384–91.CrossRefPubMedGoogle Scholar
  30. 30.
    Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, et al. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget. 2016;. doi: 10.18632/oncotarget.13699.Google Scholar
  31. 31.
    Schneider BJ, Shah MA, Klute K, Ocean A, Popa E, Altorki NK, et al. Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma. Clin Cancer Res. 2017;23:2673–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, et al. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Investig New Drugs. 2012;30:1950–7.CrossRefGoogle Scholar
  33. 33.
    Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, et al. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: an evidence review group perspective of a National Institute for Health and Care Excellence single technology appraisal. Pharmacoeconomics. 2017;35:363–73.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Yukio Kobayashi
    • 1
    • 2
  • Wataru Munakata
    • 1
  • Michinori Ogura
    • 3
    • 4
  • Toshiki Uchida
    • 3
  • Masafumi Taniwaki
    • 5
  • Tsutomu Kobayashi
    • 5
  • Fumika Shimada
    • 6
  • Masataka Yonemura
    • 6
  • Fumiko Matsuoka
    • 6
  • Takeshi Tajima
    • 6
  • Kimikazu Yakushijin
    • 7
  • Hironobu Minami
    • 7
  1. 1.Department of HematologyNational Cancer Center HospitalTokyoJapan
  2. 2.Department of HematologyInternational University of Health and Welfare, Mita HospitalTokyoJapan
  3. 3.Department of Hematology and OncologyJapanese Red Cross Nagoya Daini HospitalNagoyaJapan
  4. 4.Department of HematologyTokai Central HospitalKakamigaharaJapan
  5. 5.Department of Hematology and Oncology, University HospitalKyoto Prefectural University of MedicineKyotoJapan
  6. 6.Oncology DepartmentNovartis Pharma K.K.TokyoJapan
  7. 7.Department of Medical Oncology and HematologyKobe University HospitalKobeJapan

Personalised recommendations